Rockwell Medical (NASDAQ:RMTI) Posts Earnings Results

Rockwell Medical (NASDAQ:RMTI) posted its earnings results on Thursday. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11, FiscalAI reports. Rockwell Medical had a negative net margin of 7.33% and a negative return on equity of 14.03%. The firm had revenue of $19.12 million for the quarter, compared to the consensus estimate of $18.22 million.

Here are the key takeaways from Rockwell Medical’s conference call:

• Third-quarter net sales rose 20% to $19.1 million, driven by new customers and larger orders from existing customers, including the five largest U.S. dialysis providers. Gross profit increased 37% and gross margin improved to 16% from 14% a year earlier.
• Rockwell agreed to acquire Vantive’s global hemodialysis business, adding machines, water-treatment systems, consumables, services, and manufacturing capacity. The company estimates the combined business could generate $400 million to $450 million in annual revenue, with about 90% recurring, but the transaction remains subject to approvals and is expected to close in mid-2027.
• The company reported a third-quarter net loss of $2.3 million and adjusted EBITDA of negative $300,000; cash, cash equivalents, and available-for-sale investments declined to $22.5 million from $24.8 million at the end of the prior quarter. Higher freight, material, and supply costs also weighed on gross margin.
• Rockwell withdrew its full-year 2026 guidance, citing the pending Vantive acquisition and related expenses. Management said it expects to provide full-company guidance around March, after the Form 10-K is released.

Rockwell Medical Trading Up 3.1%

NASDAQ:RMTI traded up $0.22 during trading hours on Thursday, reaching $7.30. 11,610 shares of the stock were exchanged, compared to its average volume of 40,913. The company has a market capitalization of $29.42 million, a price-to-earnings ratio of -5.45 and a beta of 1.75. The company has a quick ratio of 3.00, a current ratio of 3.25 and a debt-to-equity ratio of 0.21. The business has a 50-day moving average of $7.83 and a two-hundred day moving average of $8.11. Rockwell Medical has a twelve month low of $4.89 and a twelve month high of $12.90.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on RMTI shares. Zacks Research lowered shares of Rockwell Medical from a “hold” rating to a “strong sell” rating in a research report on Wednesday, October 14th. Wall Street Zen upgraded shares of Rockwell Medical to a “hold” rating in a research note on Saturday, July 25th. HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Rockwell Medical in a research report on Friday, September 11th. Finally, Weiss Ratings raised Rockwell Medical from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, October 8th. One equities research analyst has rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, Rockwell Medical has an average rating of “Reduce” and a consensus price target of $20.00.

About Rockwell Medical

Rockwell Medical, Inc. is a healthcare company focused on developing, manufacturing and commercializing products used in the treatment of patients with end-stage renal disease (ESRD) who receive hemodialysis. The company supplies products intended to support anemia management and other aspects of dialysis care. Its principal pharmaceutical product is Triferic, an iron replacement therapy designed to deliver iron to hemodialysis patients through the dialysate. Rockwell Medical also markets Triferic AVNU, an intravenous formulation administered during hemodialysis.